Last reviewed · How we verify
NCT07200583: PAIA-Haplo
Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients
trial testing Protein A immunoadsorption in Hematologic Malignancies in 50 participants. Completed in 31 August 2025.
31 August 2025
Quick facts
| Lead sponsor | Ting YANG |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 31 May 2025 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 August 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Protein A immunoadsorption
- Rituximab (optional, in some patients) — full drug profile →
- Bortezomib (optional, in some patients) — full drug profile →
Conditions studied
- Hematologic Malignancies — all drugs for Hematologic Malignancies →
- Hematologic Disorders — all drugs for Hematologic Disorders →
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — all drugs for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) →
- Graft Failure — all drugs for Graft Failure →
Sponsor
Ting YANG — full company profile →
Who can join
Eligibility, any sex, with Hematologic Malignancies or Hematologic Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study reviews patients who received haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Some patients develop donor-specific antibodies (DSA), which can block engraftment and cause transplant failure. Before transplant, a treatment called protein A immunoadsorption (a blood purification method to remove antibodies) was used, sometimes with additional medications. The study aims to see whether this approach lowers antibody levels, increases the chance of successful engraftment, reduces complications such as infections or graft failure, and improves short-term survival. The results may help guide safer and more effective transplants for highly sensitized patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07200583
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Protein A immunoadsorption
Trials testing the same drug.
- NCT06763848 — Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder · NA · recruiting
Other recruiting trials for Hematologic Malignancies
Currently open trials in the same condition.
- NCT04546945 — Aberrant Expression of CD56 in Patients With Hematologic Malignancies. · recruiting
- NCT06926595 — Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention · Phase 2 · recruiting
- NCT07186192 — Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy · Phase 3 · recruiting
- NCT07195916 — A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies · Phase 1 · recruiting
- NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting
Other Ting YANG trials
Trials by the same sponsor.
- NCT07210242 — HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCR · not yet recruiting
- NCT07188077 — Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma · recruiting
- NCT07198230 — Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relap · recruiting
- NCT05785195 — A Mechanistic Study of Inhaled Nitric Oxide in COPD · NA · unknown
- NCT05466396 — Lung Health of Early COPD: A Multi-center Cohort Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07200583 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ting YANG
- Last refreshed: 18 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07200583.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing